CCRM signs agreements with Canadian and international institutions to advance regenerative medicine inventions
May 31, 2021 (Toronto, ON) – Regenerative medicine holds enormous promise to revolutionize the treatment of chronic diseases. Worldwide, universities and research hospitals are producing leading-edge research in this field, as demonstrated by the high volume of publications in recent years. However, to bring discoveries from the lab to patients, researchers must be able to commercialize their work by securing the necessary financing and expertise.
NTrans Technologies closes Series A investment to accelerate development of gene editing therapy
May 27, 2021
Utrecht, The Netherlands – NTrans Technologies (NTrans), a leader in gene editing technologies, today announced a Series A investment of 2 million Euros, led by Essential Investments, together with BOP Capital, Utrecht Health Seed Fund, and Starfish Innovations. Through this investment, NTrans aims to advance the development of its gene editing-based therapy for Duchenne Muscular Dystrophy (DMD). The funds will be used to demonstrate preclinical efficacy and safety of the therapy in DMD disease models, in preparation for its progression to the clinic.
LUMC collaborates with French therapy developer HORAMA to develop gene therapy for genetic eye disease
The Leiden University Medical Center (LUMC) has exclusively licensed its recently developed gene therapy program to treat Inherited Retinal Dystrophy to French therapy developer HORAMA for further clinical development.